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Abstract
Purpose The purpose of this work was the development of
an orthotopic model of osteosarcoma based on luciferase-
expressing tumour cells for the in vivo imaging of
multidrug resistance (MDR) with 99mTc-sestamibi.
Methods Doxorubicin-sensitive (143B-luc+) and resistant
(MNNG/HOS-luc+) osteosarcoma cell lines expressing
different levels of P-glycoprotein and carrying a luciferase
reporter gene were inoculated into the tibia of nude mice.
Local tumour growth was monitored weekly by biolumi-
nescence imaging and X-ray. After tumour growth, a 99mTc-
sestamibi dynamic study was performed. A subset of
animals was pre-treated with an MDR inhibitor (PSC833).
Images were analysed for calculation of 99mTc-sestamibi
washout half-life (t1/2), percentage washout rate (%WR)
and tumour/non-tumour (T/NT) ratio.
Results A progressively increasing bioluminescent signal
was detected in the proximal tibia after 2 weeks. The t1/2 of
99mTc-sestamibi was significantly shorter (p<0.05) in drug-
resistant MNNG/HOS-luc+ tumours (t1/2=87.3±15.7 min)
than in drug-sensitive 143B-luc+ tumours (t1/2=161.0±47.4
min) and decreased significantly with PSC833 (t1/2=173.0±
24.5 min, p<0.05). No significant effects of PSC833 were
observed in 143B-luc+ tumours. The T/NT ratio was
significantly lower (p<0.05) in MNNG/HOS-luc+ tumours
than in 143B-luc+ tumours at early (1.55±0.22 vs 2.14±
0.36) and delayed times (1.12±0.11 vs 1.62±0.33). PSC833
had no significant effects on the T/NT ratios of either
tumour.
Conclusion The orthotopic injection of tumour cells provides
an animal model suitable for functional imaging of MDR. In
vivo bioluminescence imaging allows the non-invasive
monitoring of tumour growth. The kinetic analysis of
99mTc-sestamibi washout provides information on the func-
tional activity of MDR related to P-glycoprotein expression
and its pharmacological inhibition in osteosarcoma.
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Introduction
Osteosarcoma (OS) is the most common primary malignant
bone tumour and occurs most frequently in children and
adolescents. Advances in treatments, including multiagent
chemotherapy regimens, have increased considerably the
long-term disease-free survival rates, up to 50–80% [1–4].
However, 25–50% of patients without evidence of metas-
tasis at diagnosis subsequently develop systemic disease,
Eur J Nucl Med Mol Imaging (2007) 34:1793–1803
DOI 10.1007/s00259-007-0480-8
C. M. F. Gomes :M. Welling : E. K. J. Pauwels
Department of Radiology, Section of Nuclear Medicine,
Leiden University Medical Center,
Leiden, The Netherlands
S. Romeo : P. C. W. Hogendoorn :A. M. Cleton-Jansen
Department of Pathology, Leiden University Medical Center,
Leiden, The Netherlands
I. Que :N. V. Henriquez :G. van der Pluijm
Department of Endocrinology, Leiden University Medical Center,
Leiden, The Netherlands
C. M. F. Gomes (*) :A. J. Abrunhosa :M. F. Botelho
IBILI - Faculty of Medicine,
Institute of Biophysics/Biomathematics,
Az. de Sta. Comba, Celas,
3000-354 Coimbra, Portugal
e-mail: cgomes@ibili.uc.pt
mostly related to poor response to chemotherapy [2–4]. So
far, the histological response to pre-operative neoadjuvant
chemotherapy based on the Huvos grading system is the sole
reliable predictive parameter for survival in non-metastatic
OS [1–3, 5]. Nevertheless, this prognostic marker is
ineffective in altering the outcome of poor responders, and
no survival benefit has been demonstrated with the increase
in drug dosage in histological poor responders [5–7].
Moreover, it was recently shown that histological response
but not survival improved in OS patients treated with
intensified chemotherapy [8]. Distant tumour relapses in
OS are likely to be, at least partly, due to drug resistance.
Multidrug resistance (MDR) to chemotherapy is associated
with a myriad of mechanisms that decrease drug cytotoxicity
in tumour cells. The most common involves an increased
efflux of a broad range of hydrophobic cytotoxic drugs,
mediated by the overexpression of ATP-binding cassette
(ABC) transporters, such as P-glycoprotein (Pgp), multidrug
resistance-associated protein-1 (MRP1) and breast cancer-
related protein (BCRP) [9–11].
In vitro and clinical observations have shown that the
overexpression of Pgp at the time of diagnosis is associated
with drug resistance, tumour recurrence and poor outcome in
OS patients, suggesting that Pgp overexpression could be used
as a prognostic factor [12–14]. However, other studies have
failed to confirm this relationship and the role of Pgp as a
prognostic marker remains controversial [15, 16]. This
controversy could partly be attributed to substantial method-
ological differences between studies with respect to tissue
collection methodologies, molecular targets (mRNA versus
protein) and the timing of Pgp assessment (pre-chemotherapy
or post-chemotherapy). Furthermore, common chemothera-
peutic regimens in OS include doxorubicin, a substrate of
Pgp, but also methotrexate and cisplatin, which are substrates
for other MDR transporters acting independently of Pgp.
99mTc-sestamibi, a tumour-seeking agent, has been rec-
ognised as a substrate for Pgp and MRP1 [17–19]. Several
studies have reported that absence or reduced uptake of
99mTc-sestamibi may serve to predict poor response to
therapy in several human malignant tumours, including
lymphoma, lung cancer and breast cancer [17, 20–22].
To date, only a few clinical studies have been published
on the prognostic value of 99mTc-sestamibi imaging in OS,
and its relevance in predicting tumour response remains
unclear. Burak et al. [23, 24] found a significant correlation
between the washout rate of 99mTc-sestamibi and both Pgp
and MRP1 expression in OS patients, whereas Gorlick et al.
[25] could not identify a significant correlation between
99mTc-sestamibi scintigraphic parameters and measure-
ments of Pgp expression or histological necrosis in high-
grade OS patients. The limited number of cases studied
together with the absence of standardised criteria and a
reliable index reflecting the Pgp-mediated outward trans-
port can explain these discrepancies. Furthermore, other
ABC transporters such as MRP1 and BCRP can confer
drug resistance [26, 27] and have not been extensively
studied in OS.
Previous results obtained by our group showed that
human OS cell lines, not previously selected for drug
resistance, display different expression patterns of MDR-
associated transporters (Pgp, MRP1 and BCRP) [28].
Studies on chemosensitivity to drugs used in the recently
started EURAMOS protocol (doxorubicin, cisplatin and
methotrexate) revealed that chemosensitivity to doxorubicin
is strongly dependent on Pgp expression, which can be
circumvented by addition of cyclosporine A, a potent
inhibitor of Pgp. Moreover, both uptake and efflux kinetics
of 99mTc-sestamibi were significantly correlated with Pgp
expression and sensitivity to doxorubicin [28].
These results led us to investigate the ability of functional
imaging using 99mTc-sestamibi to identify Pgp-mediated
drug resistance in animal models of OS. Most in vivo
studies have been performed in animal models with
subcutaneous tumours. These models cannot reproduce
the pathophysiological basis for tumour growth and lack
the influence of the specific organ microenvironment on the
biological behaviour of tumour cells. The orthotopic
implantation of tumour cells in the tibia or femur of mice
results in a primary tumour growth consistent with OS [29].
Cancer cell lines stably transfected either with the firefly
luciferase (Luc) or the green fluorescent protein (GFP) have
been used to monitor in living mice the local tumour
growth and the development of metastasis to different
organs [30, 31].
In this study we developed an orthotopic model of
human OS based on luciferase-expressing OS cells with
different chemosensitivity for in vivo imaging of MDR and
pharmacological inhibition using 99mTc-sestamibi. Local
tumour growth was monitored by whole-body biolumines-
cence imaging (BLI).
Materials and methods
Cell culture and transfection
Human OS cell lines MNNG/HOS and 143B were
purchased from the American Type Culture Collection
(ATCC; Rockville, MD, USA). Both MNNG/HOS and
143B are derived from the same cell line (TE85) but
MNNG/HOS resulted from pre-treatment N-methyl-N-ni-
tro-N-nitroguanidine (MNNG) and 143B was virus trans-
formed. This accounts for their differences in proliferation
and drug resistance profiles [28, 32].
In previous work, we demonstrated that MNNG/HOS is
a doxorubicin-resistant Pgp-expressing cell line, whereas
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143B expresses lower levels of Pgp and is sensitive to
doxorubicin [28]. Measurements of Pgp mRNA expression
levels by quantitative reverse transcriptase polymerase
chain reaction show mRNA expression of Ppg in relation
to control osteoblasts to be significantly higher (p<0.01) in
MNNG/HOS cells (3.7±0.34) than in 143B cells (2.5±
0.20) [28].
Cells were maintained in RPMI 1640 (Gibco, Invitrogen,
Life Technologies, Scotland, UK) supplemented with 10%
heat-inactivated foetal calf serum (Gibco) at 37°C in a
humidified incubator with 5% CO2.
143B cells were transfected with a cytomegalovirus
(CMV) promoter-driven mammalian expression vector for
firefly luciferase (CMV-luc) using FuGene (FuGene-6; Roche
Biochemicals, Almere, The Netherlands) according to the
manufacturer’s protocol. CMV-lucwas generated by cloning a
full-length firefly luciferase cDNA into the pcDNA3.1
plasmid [33] (Invitrogen, Breda, The Netherlands). Owing
to a lack of luciferase activity with the CMV-luc construct,
MNNG/HOS cells were transfected with the mammalian
elongation factor 1-alpha (EF1α). EF1α was excised as a
Hind-III fragment from the pEF-DEST51 vector (Invitrogen)
and inserted into pcDNA3.1 after removal of the CMV
promoter with NruI and NheI (Promega GmbH, Mannheim,
Germany). Transfected cells were then selected with G418
(0.3 mg/ml, Life Technologies, Basel, Switzerland) and
surviving colonies were screened for expression of luciferase
activity using the enzymatic assay on lysates (Promega kit).
Bioluminescent, G418-resistant cells (143B-luc+ and
MNNG/HOS-luc+) were expanded and used for further in
vivo whole-body BLI and for scintigraphy with 99mTc-
sestamibi. All the cell cultures were harvested at subcon-
fluency after being refreshed with medium not containing
neomycin 24 h before animal inoculation.
Animals
Eighteen female nude (BALBc nu/nu) mice, 6–8 weeks old,
were purchased from Taconic (Germany N.Y.) and housed
under pathogen-free conditions in individual ventilated
cages. Sterile food and water were provided ad libitum.
All animal studies were performed in compliance with the
Dutch laws relating to the conduct of animal experiments
and were approved by the local Committee for Animal
Experiments.
Orthotopic animal model of osteosarcoma
Mice were anaesthetised by intraperitoneal injection of 50 μl
of a freshly prepared mixture of ketamine HCl (100
mg/ml Nimatek,Vetimex Animal Health B.V., Bladel, The
Netherlands)/xylazine (2% Rompun, Bayer AG, Leverkusen,
Germany)/PBS (pH=6.8) (1:1:1). The animal model was
established by intraosseous inoculation of cancer cells in the
right tibiae as described previously [31]. In brief, two holes,
4–5 mm apart, were drilled through the bone cortex of the
upper right tibia using a 30-G needle. The bone marrow
was flushed out with PBS and a single-cell suspension
(1×105/10 μl PBS) was slowly inoculated with a 30-G
needle in the upper hole. Finally, the lower and upper holes
were sealed with surgical wax and the subcutaneous wound
was stitched. Local tumour growth was monitored weekly
by BLI and by radiography for formation of osteolytic
lesions.
Whole-body bioluminescence imaging
BLI of tumours induced by luciferase-expressing cell lines
was performed with the animals under isofluorane anaes-
thesia (0.8 L/min, isofluorane, Air Products, Waddinxveen,
The Netherlands) using the XGI-8 gas anaesthesia system
(Xenogen). The animals were injected intraperitoneally
with D-luciferin sodium salt (Synchem, BHg, Germany) at
a dose of 150 mg/kg body weight and transferred to a light-
tight chamber for acquisition of a reference grey-scale body
surface images using a Xenogen IVIS 100 imaging system
(Xenogen). Five minutes after administration of D-luciferin,
photon emission was integrated for a period of 10 s. Grey-
scale images and bioluminescent images were superim-
posed and processed using the Living Image (Xenogen
Corp, Almeda, CA) and the IGOR software (WaveMetrics
Corp, Lake Oswego, OR) for image analysis. The relative
light intensity was visualised by pseudocolours. A region of
interest (ROI) was drawn over the tumour area for
quantification of the bioluminescent signal. Data are pre-
sented as cumulative photon counts collected within each
ROI (photons/s/cm2/sr).
Detection of bone lesions by radiography
The formation of osteolytic lesions was monitored by
radiography (Kodac EDR-2 film, Eastman Kodac Co,
Rochester, NY) using an X-ray system (Faxitron 43805XR,
Hewlett Packard).
Scintigraphic imaging with 99mTc-sestamibi
and biodistribution studies
Sestamibi (Bristol-Myers Squibb Medical Imaging, Brus-
sels, Belgium) was reconstituted and radiolabelled with
sodium pertechnetate obtained from a freshly eluted
99Mo/99mTc generator (Mallinckrodt Medical, Petten, The
Netherlands) in saline according to the manufacturer’s
instructions. Radiolabelling efficiency was always higher
than 95%. A stock solution of the PSC833 (gift from
Novartis, Basel, Switzerland) was prepared in ethanol/
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tween/water (4:1:5) and diluted with saline for intraperito-
neal injection of 50 mg/kg body weight. Half of the animals
were treated with PSC833 60 min before injection of 99mTc-
sestamibi.
PSC833 is a non-immunosuppressive cyclosporine de-
rivative and has been widely reported to be a potent
inhibitor of the Pgp transporter in vitro and in vivo [34–37]
as well as in clinical trials [38, 39]. The dosage of PSC833
was based on previous reports [36, 37].
Image acquisition was performed with a single-head
gamma camera (Toshiba GCA 7100/UI, Japan) equipped
with a low-energy, high-resolution, parallel-hole collimator.
Mice were anaesthetised with i.p. injection of 50 μl of a
mixture of medetomidine (0.5 mg/kg, Domitor, Pfizer,
Espoo, Finland), midazolan (5 mg/kg, Dormicum, Roche,
Woerden, The Netherlands) and fentanyl (0.05 mg/kg), and
placed on the collimator in a supine position. 99mTc-
sestamibi (10 MBq/0.1 ml) was slowly administered into
the left cardiac ventricle. Immediately thereafter, whole-
body dynamic images were acquired every minute for
1 h (matrix size 128×128).
For image processing, a ROI was drawn on the right leg
over the tumour area (T) in the frame showing highest
radioactivity and then applied to the entire series of
dynamic images. A symmetrical ROI of the same size
was set on the contralateral side to determine the radioac-
tivity of the non-tumour area (NT). Tumour to non-tumour
ratios (T/NT) were calculated on both early (5 minutes) and
delayed images (60 min). Time-activity curves over the
tumour area were generated after decay correction, normal-
ised to the maximum activity and fitted to a mono-
exponential function by the method of least squares using
the Origin software package (OriginLab, Northampton,
MA). The washout half-time (t1/2) and the percentage
washout rate (%WR) of 99mTc-sestamibi from the tumour
area were calculated as previously described [23, 25].
After imaging acquisition, the animals were sacrificed
by cervical dislocation. Tibia containing tumour and
samples of blood, heart, skeletal muscle and normal tibia
were harvested, weighted and assayed for radioactivity in
a well-type sodium iodide γ-counter (SR3, Nuclear
Enterprises, Reading, UK) within the 99mTc-sensitivity
energy window set as 20%. Tissue radioactivity was
expressed as a percentage of the total dose injected per
gram (% ID/g).
Histological analysis
Tumour samples were subsequently fixed in 10% buffered
formalin, decalcified with 10% EDTA and processed for
paraffin embedding. Sections of 4–6 μm were cut and
stained with haematoxylin and eosin (H&E) for histological
analysis as previously described [31, 40].
Statistical analysis
All data are given as mean ± SD. Statistical analysis was
performed using the unpaired t test for comparisons
between two variables within a group or ANOVA for
multiple comparisons. P values<0.05 were considered
statistically significant.
Results
In vivo monitoring of orthotopic tumour growth
Positive bioluminescent cells, 143B-luc+ and MNNG/HOS-
luc+ were inoculated directly into the right tibia of nude
mice. Local tumour growth was monitored weekly by BLI
and by radiography for formation of osteolytic lesions.
Eighty percent of mice inoculated with 143B-luc+ cells
(n=10) developed tumours. Of these, only 50% showed
detectable bioluminescent signals at 2 weeks after inocula-
tion. Figure 1a shows a representative mouse inoculated
with 143B-luc+ cells. A very low signal was registered at
the second week, which had increased 28-fold after 3 weeks
and afterwards remained approximately constant (Fig. 1a,
Table 1). In contrast, the external tumour volume, measured
with a calliper, increased from 70.2±14.5 mm3 to 106.3±
18.4 mm3 between the third and fourth weeks. Due to bone
resorption stimulated by tumour cells, tumour progresses
and invades the surrounding tissues around the tibia,
becoming palpable at 3 weeks.
All mice inoculatedwith theMNNG/HOS-luc+ cells (n=8)
developed tumours and showed progressive tumour growth
indicated by the gradual increase in the bioluminescent
signal over time. The first signal was detected 1 week after
cell inoculation and thereafter increased substantially, rising
97-fold at 4 weeks (Fig. 1d, Table 1). The external tumour
volume, measurable after 3 weeks, increased from 57.5±20.1
mm3 to 98.3±14.5 mm3 between the third and the fourth
week. Bioluminescence images clearly demonstrated a
difference in the signal intensity between MNNG/HOS-luc+
and 143B-luc+ tumours. The cumulative photon count
(photons/s/cm2/sr) calculated from the ROI drawn over
tumours was markedly higher in MNNG/HOS-luc+ tumours
(∼30–40 fold) than in 143B-luc+ tumours (Table 1).
Radiographs taken at equivalent time points showed initial
signs of osteolysis at 3 weeks and these signs became clearly
evident at 4 weeks, as illustrated by areas of low mineral
content and erosion of the cortical bone for both tumours
(Fig. 1b,e).
Histological analysis of both 143B-luc+ and MNNG/
HOS-luc+ tumours demonstrated a high-grade sarcoma
morphologically consistent with human OS. Representative
images are shown in Fig. 1c and f, respectively.
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Tumour visualisation with 99mTc-sestamibi
After primary tumour growth, whole-body imaging with
99mTc-sestamibi was performed to assess the functional
activity of Pgp in tumours and to evaluate the inhibitor
effects of PSC833 on Pgp activity.
Both 143B-luc+ and MNNG/HOS-luc+ tumour-bearing
mice were imaged at 4 weeks after cell inoculation. Figure 2
shows representative dynamic images of 99mTc-sestamibi in
143B-luc+ tumour mice without treatment (a) and after
treatment with PSC833 (b). All 143B-luc+ tumours were
clearly visualised at the right tibia within the first 5 min after
injection of 99mTc-sestamibi and remained visible during the
60-min acquisition period, although some activity was
washed out from the tumours (Fig. 2a). The images acquired
from animals treated with PSC833 (50 mg/kg) showed an
increase in both uptake and retention of 99mTc-sestamibi in
143B-luc+ tumours (Fig. 2b).
Representative dynamic images from mice with MNNG/
HOS-luc+ tumours are shown in Fig. 3. The MNNG/HOS-
luc+ tumours were visualised within 1–5 min following
injection of 99mTc-sestamibi, but exhibited lower accumu-
lation of 99mTc-sestamibi and less retention of activity
compared with 143B-luc+ tumours (Fig. 3a). Treatment
with PSC833 increased the tumour uptake and substantially
decreased the washout rate of 99mTc-sestamibi compared
with untreated MNNG/HOS-luc+ animals (Fig. 3b).
Time-activity curves and kinetic parameters of 99mTc-
sestamibi, obtained from imaging analysis, are shown in
Fig. 4 and Table 2, respectively. For time-activity curves,
the tumour activity was normalised as percentage of peak
activity obtained 2–3 min post-injection. The washout half-
times of 99mTc-sestamibi were significantly (p<0.05) longer
in 143B-luc+ tumours (t1/2=161.0±47.4 min) than in
MNNG/HOS-luc+ tumours (t1/2=87.3±15.7 min). Admin-
istration of PSC833 increased significantly (p<0.05) the
washout half-times of 99mTc-sestamibi in MNNG/HOS-luc+
tumours (t1/2=173.0±24.5 min) to values comparable to
those in 143B-luc+ tumours. In contrast, no significant
effects of PSC833 on the washout half-times of 99mTc-
sestamibi in 143B-luc+ tumours (p>0.05) were observed
(Table 2).
Table 1 Progression of bioluminescent signals in MNNG/HOS-luc+ and 143B-luc+ tumours growing in tibia of nude mice over 4 weeks
Tumour Bioluminescent signal (p/s/cm2/sr)
Week 1 Week 2 Week 3 Week 4
MNNG/HOS-luc+(n=8) 34,116±15,252 154,657±31,389 2,228,340±424,765 3,300,566±181,221
143B-luc+ (n=5) ND 2,430±212 69,208±23,122 71,006±23,650
p/s/cm2 /sr photons per second per square centimetre per steradian, ND not detected
Fig. 1 Monitoring of orthotopic
tumour growth in nude mice.
Representative bioluminescent
images after intratibial inocula-
tion of 143B-luc+ cells (a) and
MNNG/HOS-luc+ (d) cells over
4 weeks. Luminescence signal is
presented as photons/s/cm2/sr.
Radiographs taken at 4 weeks
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The percentage washout rate (%WR) was significantly
higher in MNNG/HOS-luc+ than in 143B-luc+ tumours
(37.5%±4.0% vs 24.6%±7.5%, p<0.05). PSC833 decreased
significantly the %WR in MNNG/HOS-luc+ tumours (%
WR=21.7%±2.5%, p<0.05) and had no significant effects
on 143B-luc+ tumours (%WR=19.4%±1.9%, p>0.05)
(Table 2).
The T/NT ratios of 99mTc-sestamibi on early (5 min) and
delayed (60 min) images were significantly (p<0.05) higher
in 143B-luc+ tumours (2.14±0.36 and 1.62±0.33, respec-
tively) than in MNNG/HOS-luc+ tumours (1.55±0.22
and 1.12±0.11, respectively) (Table 2). PSC833 had no
significant effects on either early or delayed T/NT ratios in
143B-luc+ tumours. Although administrations of PSC833
increased the T/NT ratios in MNNG/HOS-luc+ tumours, the
differences were not statistically significant (p>0.05).
Biodistribution data
The imaging results were confirmed by biodistribution
analysis in tumours and organ samples (Table 3) at 2 h after
99mTc-sestamibi injection. The Pgp-expressing MNNG/
HOS-luc+ tumours accumulated significantly less 99mTc-
sestamibi compared with the 143B-luc+ tumours (%ID/
g=0.87±0.21 vs 1.79±0.82, p<0.05). Treatment with
PSC833 increased significantly (p<0.05) the accumulation
of 99mTc-sestamibi in MNNG/HOS-luc+ (%ID/g=1.32±
0.31) tumours and had no significant effect in 143B-luc+
tumours (%ID/g=2.27±0.42, p>0.05). 99mTc-sestamibi
whole-body distribution showed normal physiological
values with highest accumulation in the heart, liver and
kidney, and did not differ significantly between mice
bearing 143B-luc+ or MNNG/HOS-luc+ tumours. No
significant differences were observed after treatment with
PSC833.
Discussion
This study was designed to assess the ability of 99mTc-
sestamibi imaging to detect Pgp-mediated multidrug resis-
tance in OS. For that purpose we developed a clinically
relevant animal model of OS by orthotopic injection of
human OS cells in mice. Tumour growth and progression
were monitored using BLI and conventional radiology
techniques. Two established human OS cell lines (143B,
MNNG/HOS) with different chemosensitivity to doxorubi-
cin and expressing different levels of Pgp were successfully
transfected with firefly luciferase and inoculated directly
into the proximal tibia of nude mice.
The orthotopic inoculation of tumour cells promoted the
development of local intratibial tumours. The high sensi-
tivity of BLI permitted the continuous monitoring of tumour
progression from the early stages of development (1–2
weeks) to the time of 99mTc-sestamibi imaging (4 weeks). In
contrast to BLI, conventional radiography was only useful
in the later stages of tumour development (3–4 weeks),
when the first signs of osteolytic lesions became evident.
Moreover, osteolysis is an indirect, late and inconsistent
Fig. 3 Representative 99mTc-sestamibi dynamic images of mice
bearing orthotopic MNNG/HOS-luc+ tumours in the right tibiae.
Animals were imaged at 4 weeks after tumour cell inoculation,
without PSC833 (a) and after treatment with 50 mg/kg PSC833 (b)
Fig. 2 Representative 99mTc-sestamibi dynamic images of mice
bearing orthotopic 143B-luc+ tumours in the right tibiae. Animals
were imaged at 4 weeks after tumour cell inoculation, without PSC833
(a) and after treatment with 50 mg/kg PSC833 (b)
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sign of tumour progression and does not take into account
the extension into the surrounding soft tissues.
Several factors can account for the differences observed
in the intensity and progression of bioluminescent signal
between the MNNG/HOS-luc+ and 143B-luc+ tumours.
The 143B cell line was transfected under the control of the
CMV promoter; whereas MNNG/HOS was transfected
under control of EF1α, since the CMV promoter did not
result in detectable luciferase activity in MNNG/HOS. The
activity of the CMV promoter depends on the cell cycle
stage and medium composition [41]. It was shown that
changes in the CMV promoter activity, induced by DNA
methylation and histone deacetylation, can silence the gene
expression and decrease the signal intensity during in vivo
imaging [42]. Moreover, the bioluminescence emission
requires the presence of D-luciferin in tumour cells. This
substrate is oxidised by luciferase in the presence of co-
factors (oxygen, adenosine triphosphate and magnesium).
Inefficient cell uptake of D-luciferin due to alterations in
tumour blood supply and cell membrane permeability
decreases the luciferase activity. Scatena et al. [43] also
observed constant bioluminescent signals in prostate
tumours despite the 3.3-fold increase in tumour volume.
This indicates that luciferase expression can be lost in time,
probably owing to genomic instability.
Additionally, although the recorded bioluminescent
intensity depends linearly on the proliferation of lucifer-
ase-expressing cells, it also has a strong non-linear
dependence on tumour depth owing to attenuation and
scattering of emitted light by overlying tissues and tumour
optical properties [30, 44]. This is an inherent feature of this
imaging modality. Therefore, the intensity of the biolumi-
nescent signal may not always be taken as a direct measure
of cell proliferation.
To date, most in vivo studies on MDR have been
performed in experimental models with subcutaneous
tumours. In these models, tumour cells are selected in vitro
for the MDR phenotype by exposure to anticancer drugs
and then injected subcutaneously in the back or flank of
nude mice. Although these models are adequate for specific
assays, such as the rapid screening of new compounds, they
cannot reproduce the physiological environment, which
Table 2 Effects of PSC833 on 99mTc-sestamibi kinetic parameters in 143B-luc+ and MNNG/HOS-luc+ tumours
Parameter 143B-luc+ MNNG/HOS-luc+
MIBI MIBI+PSC833 MIBI MIBI+PSC833
t1/2 (min) 161.0±47.4 195.2±21.0 87.3±15.7* 173.0±24.5**
WR (%) 24.6±7.5 19.4±1.9 37.5±4.0* 21.7±2.5**
T/NT5 min 2.14±0.36 2.07±1.10 1.55±0.22* 2.33±0.70
T/NT60 min 1.62±0.33 1.67±0.84 1.12±0.11* 1.85±0.64
Results are expressed as mean ± SD of at least four mice
MIBI 99m Tc-sestamibi, t1/2 washout half-time, WR (%) percentage washout rate, T/NT5 min tumour/non-tumour ratio at 5 min, T/NT60 min tumour/
non-tumour ratio at 60 min
*p<0.05 compared with 143B-luc+ tumours without PSC833
**p<0.05 compared with MNNG/HOS-luc+ tumours without PSC833
Fig. 4 Time-activity curves of
99mTc-sestamibi in 143B-luc+
(a) and MNNG/HOS-luc+ (b)
tumours in the absence (■) and
in the presence (□) of PSC833.
The radioactivity over the tu-
mour area was normalised to the
maximum activity obtained 2–3
min post-injection and corrected
for physical decay
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influences the biological behaviour of tumour cells. In fact,
Dong et al. [45] demonstrated that the organ environment
influences the Pgp expression in colon carcinoma cells,
affecting their in vivo sensitivity to doxorubicin. The Pgp
gene expression depends on a variety of host factors such as
interaction with the extracellular matrix and environmental
mitogenic signals [46, 47]. This fact underlines the critical
role of the specific organ microenvironment on tumour
development and gene expression. To our knowledge this is
the first application of an orthotopic model of OS for
molecular imaging of MDR using radiotracers. Moreover,
we used human OS cell lines not previously selected for
drug resistance, a condition closer to the clinical setting.
The results we obtained suggest that differences in Pgp
expression in OS can be detected non-invasively by
scintigraphic imaging with 99mTc-sestamibi. In our study,
a 1-h tracer kinetic analysis detected a faster washout rate
of 99mTc-sestamibi in the MNNG/HOS-luc+ tumours when
compared with the 143B-luc+ tumours. T/NT ratios on both
early (5 min) and delayed (60 min) images were also
significantly reduced in MNNG/HOS-luc+ cells when
compared with 143B-luc+ tumours. These findings are
largely consistent with our previous results from in vitro
studies in the same cell lines, indicating that the reduced
uptake and the faster washout rate of 99mTc-sestamibi are
associated with higher expression of Pgp in the MNNG/
HOS cell line [28]. This conclusion is strengthened by the
fact that the pharmacological inhibition of Pgp using a
specific inhibitor (PSC833) led to a significant decrease in
the 99mTc-sestamibi efflux rate in Pgp-expressing tumours
(MNNG/HOS-luc+).
The clinical relevance of 99mTc-sestamibi in predicting
chemotherapy response has been investigated in several
tumours. Some authors have reported an inverse correlation
between tumour-to-background ratio, usually measured at
delayed times, and Pgp expression in tumours [22, 48, 49].
Other reports suggest that enhanced tracer clearance is an
index of Pgp function and might predict Pgp-mediated
resistance to chemotherapy and treatment failure [21, 24,
50, 51]. Our results indicate that both uptake and washout-
related parameters discriminate these tumours based on
differential expression levels of Pgp. However, the washout
half-time appears to be a better predictor of drug resistance,
as it results in a twofold difference between MNNG/HOS-
luc+ and 143B-luc+, as compared with the 1.4-fold
difference observed for T/NT (early and delayed) ratios
and %WR. Moreover, the washout half-life appears to be a
more reliable index than %WR, which is subjected to
higher variability depending on the delayed imaging time.
Despite our encouraging results, the prognostic value of
99mTc-sestamibi uptake for tumour response should be
carefully evaluated. The absence or reduction of 99mTc-
sestamibi uptake on early images may suggest that 99mTc-
sestamibi uptake can also be influenced by other factors,
rather than simply Pgp activity. Inefficient blood supply,
advanced cell necrosis, hypoxia and the overexpression of
the apoptotic protein Bcl-2 may significantly reduce the
uptake of 99mTc-sestamibi in tumour lesions [52]. Aloj et al.
[53] found a significant correlation between the absence of
99mTc-sestamibi uptake and overexpression of Bcl-2 in
breast cancer cell lines. Multidrug resistance-associated
protein 1 (MRP1) can also be overexpressed in tumour
cells, conferring drug resistance [23, 54]. Decreased uptake
or enhanced efflux of 99mTc-sestamibi can be mediated by
MRP1 [19, 23]. In this model, the hypothesis of MRP1-
mediated outward transport of 99mTc-sestamibi is excluded
since our previous studies found that MRP1 is equally
expressed in 143B and MNNG/HOS cell lines [28].
In the present study we also showed that the outward
transport of 99mTc-sestamibi in Pgp-expressing tumours can be
reduced by pre-treatment with PSC833, a potent Pgp inhibitor.
PSC833 increased significantly the washout half-life and
Table 3 Biodistribution data (%ID/g) of 99mTc-sestamibi in tumour-bearing nude mice at 2 h after infection
Organ 143B-luc+ MNNG/HOS-luc+
MIBI MIBI+PSC833 MIBI MIBI+PSC833
Blood 0.13±0.04 0.18±0.06 0.19±0.07 0.21±0.05
Heart 20.84±6.67 23.94±4.87 24.65±7.54 26.87±5.86
Lung 3.03±1.01 3.61±1.79 5.03±2.81 6.13±3.26
Liver 10.12±3.47 12.14±6.94 13.02±2.06 16.39±1.56
Kidney 22.47±7.78 27.69±12.79 22.79±9.42 24.89±11.22
Normal tibia 0.22±0.15 0.52±0.35 0.54±0.27 0.48±0.19
Muscle 1.54±0.62 2.01±0.42 1.19±0.68 1.57±0.29
Tumour 1.79±0.82 2.27±0.42 0.87±0.21* 1.32±0.31**
Data are presented as mean ± SD of at least four experiments
MIBI 99m Tc-sestamibi
*p<0.05 compared with 143B-luc+ tumours without PSC833
**p<0.05 compared with MNNG/HOS-luc+ tumours without PSC833
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decreased the washout rate in MNNG/HOS-luc+ tumours to
values comparable to those observed in 143B-luc+ tumours.
Interestingly, no significant increase was observed in T/NT
ratios for MNNG/HOS-luc+ tumours after treatment with
PSC833. This indicates that the T/NT ratio is not a consistent
index for evaluation of the inhibitor effects of PSC833 on Pgp
transport activity. As mentioned above, uptake is influenced
by multiple factors other than Pgp expression. Additionally,
Pgp is expressed in several normal tissues, including muscle
tissue. As inhibition of Pgp may occur in normal tissue, the
PSC833 action affects simultaneously the two factors used to
calculate T/NT ratios, making this index less sensitive to the
inhibition of Pgp in tumours. The biodistribution data at 2
h after injection support this hypothesis. In fact, administration
of PSC833 produced an increase in 99mTc-sestamibi accumu-
lation in MNNG/HOS-luc+ tumours (1.5-fold) and in muscle
tissue (1.3-fold). As expected, administration of PSC833 had
no significant effects on the washout half-life or %WR or on
T/NT ratios in 143B-luc+ tumours. 99mTc-sestamibi biodis-
tribution in 143B-luc+ confirmed these results.
Clinical studies published on the prognostic value of
99mTc-sestamibi in OS have been few and apparently
contradictory [23–25]. The different methodologies used
for assessing Pgp expression/function, together with the
small number of patients studied, might explain the
discrepancies. Some researchers have suggested that Pgp
expression measured at diagnosis in high-grade OS should
be used as the basis for stratification therapy [55]. Our
results are encouraging and demonstrate the potential of
99mTc-sestamibi imaging in predicting tumour response and
monitoring the efficiency of MDR inhibitors in OS.
However, further clinical and pre-clinical studies are needed
for standardisation of imaging procedures and identification
of reliable and direct indexes of Pgp functional activity in
the clinical setting.
In conclusion, the orthotopic injection of cancer cells
provides a xenograft model of human OS that can be used
for functional imaging of MDR. Bioluminescence imaging
allows the continuous sensitive non-invasive monitoring of
tumour growth and progression. 99mTc-sestamibi imaging
kinetics provides valuable information on the functional
activity of Pgp expression and its pharmacological inhibi-
tion. This information could prove a very valuable tool in
the clinical setting both for its prognostic value and in the
planning of alternative therapeutic strategies in the clinical
management of poor responders in OS.
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